“Genetics and runaway appetite are not the only causes of obesity. Sometimes, your own body can turn against you in ways you never thought possible.” ~The Science of Obesity
Wednesday, November 6, 2013
Adrenal Surgery Treatment & Management
Some of you may not want to know what happens, some like me do. It is here if you want it. No graphic photos.
http://emedicine.medscape.com/article/443536-treatment#showall
Keto: It was fun while it lasted
FDA Puts Strict Limits on Oral Ketoconazole Use
Tuesday, November 5, 2013
Pituitary Disorders and the Family
| ||||||||
|
Webinar: Pituitary Disorders and the FamilyPresented ByJamie L. Banker, Ph.D. Director of Counseling Psychology
Seating is limited, register today!
Date: Friday, November 15, 2013 Webinar InformationChronic illness systemically affects individuals and families, in that the illness impacts the whole system, rather than just the individual with the diagnosis. Health problems can create or exacerbate conflict within a family or support system (Ruddy, Borresen, & Gunn, 2008). This is also the case within families with a family member with an endocrine disorder. Historically, research on medical illness focused mainly on the identified medical patient, but recent literature shows an ever-growing interest in understanding the physical and mental toll those managing and caring for close relatives with a serious illness or disability (Feigin, Barnetz, & Davidson-Arad, 2008). Family systems theories have influenced this turn, as it becomes clear that focusing on a problem with one family member acknowledges only one part of the affected system. In this presentation Dr. Banker will talk about what is meant by the "family system," what is meant by "collaborative' and "integrated" care, Dr. Banker will identify ways pituitary disorders impact the family system, She will discuss ways family members can positively impact healing and learn what can be the role of a "family therapist" in helping families affected by a pituitary tumor or other endocrine disorder. Dr. Banker will also talk about her most recent research connecting the early childhood trauma and pituitary disorders. Learning Objectives
Presenter BioJamie Banker is the Director of Counseling Psychology Masters program and Assistant Professor of Psychology at California Lutheran University in Thousand Oaks California. She is a Licensed Marriage and Family Therapist and has a special interest in integrated behavioral healthcare. She completed a clinical master's degree at University of San Diego and completed her doctoral degree at Virginia Tech. Dr. Banker was a doctoral intern at Dartmouth College Family Medicine Residency. Dr. Banker has worked in three integrated primary care practices as a therapist and a lecturer. She has published scholarly articles and a few book chapter on integrated healthcare. Now her focus is on training Marriage and Family Therapy students to work in integrated behavioral healthcare sites. She is an AAMFT approved clinical supervisor. Dr. Banker's research agenda centers on women's and family's health. It encompasses topics that are both underserved and burgeoning in the fields of psychology, marriage and family therapy, behavioral medicine, and public health. Dr. Banker's primary research interests are collaboration between family therapists and medical professionals, family health and training integrated care professionals. These interests all fall under the larger umbrella of improving individuals' overall healthcare. Her research agenda is focused on decreasing the gap between medical and mental health assessment and treatment. Dr. Banker's current research is on understanding postpartum depression and disorders of the endocrine system from a biopsychosocial model.
| ||||||||
Monday, November 4, 2013
New Chapter of my Life

Saturday, November 2, 2013
BLA takes a Patient from Cushing's to Addison's
Adrenal crisis in treated Addison's disease: a predictable but under-managed event
- Addison's Disease Self-Help Group,PO Box 1083, Guildford GU1 9HX
1School of Clinical and Experimental Medicine, Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham College of Medical and Dental Sciences, Edgbaston, Birmingham B15 2TT, UK
- (Correspondence should be addressed to K White; Email:kgwhite@addisons.org.uk)
Abstract
Context Adrenal crisis is a life-threatening event that occurs regularly in Addison's patients receiving standard replacement therapy. Patient reports suggest that it is an underestimated and under-managed event.
Objective To assess the frequency of adrenal crisis in diagnosed patients and to understand the factors contributing to the risks of adrenal crisis.
Design We conducted a postal survey of Addison's patients in four countries, UK (n=485), Canada (n=148), Australia (n=123) and New Zealand (n=85) in 2003, asking about patients' experiences of adrenal crisis and their demographic characteristics. In 2006, a shorter follow-up survey was conducted in the UK (n=261).
Method The frequency and causes of adrenal crisis were compared across both surveys. Demographic data from the 2003 survey were analysed to establish the main variables associated with an elevated risk of crisis.
Results Around 8% of diagnosed cases can be expected to need hospital treatment for adrenal crisis annually. Exposure to gastric infection is the single most important factor predicting the likelihood of adrenal crisis. Concomitant diabetes and/or asthma increase the frequency of adrenal crises reported by patients.
Conclusion The endocrinologist has a responsibility to ensure that Addison's patients have adequate access to life-saving emergency injection materials and repeated, practical training sessions in how to use them, while the general practitioner plays a vital role as in arranging prompt emergency admissions.
Patient Access to Current Medical Literature
Patient Request for Copy of an Article Recently Published by The Endocrine Society Journals
Please use this request for articles recently published in The Journal of Clinical Endocrinology & Metabolism, Endocrinology,Molecular Endocrinology, or Endocrine Reviews.
Note that all articles published more than 12 months ago back to 1997 are free to all online.
To receive your copy of the requested article, please provide the following information:
- Article information, including author(s), title of journal, title of article, issue date and page number. This information is available free online for all articles in the Table of Contents.
- Your name and e-mail address.
NOTE
For additional patient information on hormone-related conditions, free publications and a physician referral, visit The Hormone Foundation at www.hormone.org. The Hormone Foundation, the public education affiliate of The Endocrine Society, serves as a resource by promoting the prevention, treatment and cure of hormone-related conditions through outreach and education.
Monday, October 28, 2013
Reading your Rx
Thursday, October 10, 2013
SIGN THE PETITION: We deserve better than Solu Cortef
This mom is fighting to make it happen. Rachel, a British mother, desperately wants her child and family to have an easier way to administer emergency cortisol injections--like Solu-Cortef for her 14 year old daughter with hypopituitarism. Her daughter doesn't make any cortisol and relies on replacement steroids, like Addison's patients or Cushies after pituitary surgery or bilateral adrenalectomies.
Please read their story and consider signing the petition.
If you live in the United Kingdom, please sign this petition:
http://you.38degrees.org.uk/petitions/for-cortisones-sake-give-steriod-dependents-the-life-saving-injection-they-need
If you live elsewhere in the world, please sign this petition via facebook:
https://m.facebook.com/rachelpeglersavinglivesforsterioddependants/about?notif_t=page_new_likes&__user=100000742731717
Sunday, October 6, 2013
BLA "relatively safe and provides adequate success"
- Home
- |2013 Archive
- |October 2013
- |Ritzel et al. 98 (10): 3939
- Journal of Clinical Endocrinology & Metabolism
- Special Features
- Katrin Ritzel,
- Felix Beuschlein,
- Anne Mickisch,
- Andrea Osswald,
- Harald J. Schneider,
- Jochen Schopohl and
- Martin Reincke
- Address all correspondence and requests for reprints to: Martin Reincke, M.D., Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Ziemssenstrasse 1, D-80336 München, Germany. E-mail:Martin.Reincke@med.uni-muenchen.de.
Footnotes
For editorial see page 3974
Abbreviations:
- BADx
- bilateral adrenalectomy
- BAH
- bilateral adrenal hypercortisolism
- CD
- Cushing's disease
- CS
- Cushing's syndrome
- ECS
- ectopic CS
- NS
- Nelson's syndrome
- QOL
- quality of life
- TSS
- transsphenoidal surgery.
- Received February 21, 2013.
- Accepted August 5, 2013.
- Copyright © 2013 by The Endocrine Society
Friday, October 4, 2013
Brimscombe mum's plea for injection pen which could save her little girl’s life
Yes, we need the Solu-Cortef pen to be easier to dispense. My growth hormone Nutropin is so easy to do. The injectable that saves our life should be just as easy. I'm signing the petition. Will you?
Brimscombe mum's plea for injection pen which could save her little girl's life
6:02pm Monday 30th September 2013
By Hayley Mortimer
MUM Rachel Pegler has issued a heartfelt plea to SNJ readers to back a petition for health bosses to create an injection pen which could save her little girl's life.
Brimscombe schoolgirl Molly, 14, suffers from a rare condition called hypopituitarism, which can be fatal if levels of the hormone cortisol drop too low and she does not receive an injection in time.
She cannot leave the house without a life-saving kit that contains a syringe, needles and vials of hydrocortisone and her teachers at Thomas Keble School have been trained to give the jab.
Rachel is urging medical bosses to create an 'epi-pen' for this type of illness, which would enable Molly to administer her own injection in an emergency.
She has launched an online petition to get the issue raised in Parliament, which has already attracted more than 2,000 signatures.
"We currently have a very outdated style injection," said Rachel, an artist and illustrator.
"I worry that when alone and close to unconscious my little girl would not even be able to take the top off the glass tube.
"An injection pen could mean life or death."
Cortisol is a chemical hormone produced by the body to manage stress by providing a boost of blood sugar.
When Molly becomes stressed or unwell she is unable to produce enough cortisol and has to rely on extra steroids, which she takes three times a day.
If she is sick or suffers any trauma or injury she needs an emergency injection and hospital treatment.
Molly, who has an older brother Josh, 19, and younger sisters Poppy, 10, and Primrose, one, also has other health problems, which affect her immune system.
"Ultimately I would like my little girl to finally have a normal life," said Rachel.
"Molly is the most cheerful lovely girl. She loves writing scripts and fiction.
"It is such a strain on all of us when she is poorly, we all find it very hard.
"Molly has gone through so much and deserves the knowledge that no mistakes will be made in saving her life in an emergency situation."
To sign the petition go to http://tinyurl.com/o2dwoxp
© Copyright 2001-2013 Newsquest Media Group
http://www.stroudnewsandjournal.co.uk
Cortisol: The Hormone Maverick
Saturday, August 3, 2013
Help PCPs Know What How to "Treat" a Cushing's Patient
treat
[treet]
verb (used with object)
1.
to act or behave toward (a person) in some specified way: to treatsomeone with respect.
2.
to consider or regard in a specified way, and deal with accordingly: to treat a matter as unimportant.
3.
to deal with (a disease, patient, etc.) in order to relieve or cure.
This article is targeted to primary care physicians, often the first stop on a patient's path to diagnosis. Some patients face uninterested doctors with little medical curiosity. I did. You likely did. It is my hope that these physicians listen to their patients and begin to test for this not-so-rare-but-rarely-diagnosed disease. Primary Care Physicians must learn how to treat (1) Cushing's patients as much as they learn to treat (3) us. This article offers guidelines for this front-line group. -- M
When to think Cushing's syndrome in type 2 diabetes
Thursday, August 1, 2013
Pituitary damage an unexpected war wound
http://www.latimes.com/la-me-pituitary-damage-20130801,0,579258.story
Emerging evidence suggests that pituitary problems may be going undiagnosed in victims of blast-related brain injuries, the defining wounds of the recent wars.
The symptoms often overlap, perhaps explaining why some patients do not fully recover and offering hope that hormone replacement therapy might help in some cases.
Trying to get a handle on the problem, the Pentagon last year issued guidelines to its doctors to screen for hormone irregularities when symptoms persist after concussions — the mildest and most common form of traumatic brain injury, or TBI.
The pea-sized pituitary gland secretes nine hormones that help regulate metabolism, sexual function, blood pressure and other vital processes. Housed in a bony pocket in the skull, it hangs from the base of the brain by a strand of neurons and blood vessels.
Experts long have known that serious head trauma can disrupt the blood supply and nerve connections. Over the last decade, the same damage has been documented in people who suffered concussions in car crashes and sports accidents. Only in the last few years did scientists begin to look specifically at the risk from blasts."[\endquote]
Thursday, July 25, 2013
Cushing's patients will have global access to Korlym
Corcept Therapeutics Announces Partnership With Idis for Global Access to Korlym(R)
Corcept Therapeutics Announces Partnership With Idis for Global Access to Korlym(R)— Corcept Therapeutics Incorporated (NASDAQ: CORT) announced today that Korlym® (mifepristone) 300 mg Tablets is available to patients outside of the United States through an Idis Access Program. Idis Access Programs enable patients around the world to be prescribed investigational or approved drugs prior to their commercial launch in that country through a regulatory-compliant and ethical channel on a named-patient basis. Corcept, a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders, has been offering Korlym in the United States since April 2012 as a once-daily oral treatment of hyperglycemia secondary to endogenous Cushing's syndrome in adult patients who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
http://www.sys-con.com/node/2746247
Corcept is "Down but Far from Out"
Sometimes having drugs earn FDA approval or even having some good trial results to go along with good cash positions simply aren't enough to keep investors entertained. When investors lose faith or question when they will ever see a return, it can initiate selling that leaves the door open to great opportunity. For these five stocks, there has recently been more selling than buying and yet not much seems to have changed. There are some approved products that have great potential, some products in trials with some positive results and even some pretty sound cash positions to consider. The time is now right to take a second look at what they each have to offer.
....
Corcept Therapeutics (CORT)
Corcept Therapeutics has taken its share of knocks lately primarily because the marketing of its approved drug Korlym has failed to deliver anticipated results with revenue. Korlym is approved for controlling hyperglycemia associated with Cushing's syndrome and represents the first FDA-approved oral therapy for the treatment of patients with this rare disorder. Since being launched in April of 2012, revenue growth has been slow to develop. Now Korlym faces competition from Novartis (NVS) and its competing drug Signifor which also was approved for treating patients with Cushing's syndrome in December. There is more for Corcept to prove with Korlym in treating psychotic depression and there is more marketing left to do for Cushing's syndrome in order to realize some of Korlym's potential. Some hope that Novartis and their entry into the Cushing's syndrome marketplace might actually work to Corcept's favor with their first-mover advantage with Korlym and the marketing might of Novartis educating patients and physicians alike.
Corcept has been struggling to make money, but at least has experienced increasingrevenue since April of 2012 up from $875K in 2nd quarter of 2012 to $1.7 million in the 1st quarter of this current year. Corcept even has plenty of cash reporting about $81.5 million at the end of the first quarter of this year. The $11-12 million cash burn might appear to be pretty extreme, but opening up a marketplace for Korlym to treat psychotic depression should really get things going for Corcept and its stock. The stock is down 59.3% from a year ago, now at $1.79 a share, and is a little above its 52-week low of $1.27 a share. If Novartis can help educate practitioners and patients alike to further the understanding of Cushing's disease, this could be all Corcept needs to finally break out of its slump. On the other hand, if Novartis does too well or doesn't do enough, Korlym's hopes and Corcept's too will depend on the ability to treat psychotic depression. After a nice 5.9% gain on last Friday it might be a signal that some investors think it can.
Thursday, June 20, 2013
AMA declares obesity a disease
BY MELISSA HEALY AND ANNA GORMAN,Los Angeles Times
The American Medical Assn. voted Tuesday to declare obesity a disease, a move that effectively defines 78 million American adults and 12 million children as having a medical condition requiring treatment.
The nation's leading physicians organization took the vote after debating whether the action would do more to help affected patients get useful treatment or would further stigmatize a condition with many causes and few easy fixes.
In the end, members of the AMA's House of Delegates rejected cautionary advice from their own experts and extended the new status to a condition that affects more than one-third of adults and 17% of children in the United States.
"Recognizing obesity as a disease will help change the way the medical community tackles this complex issue that affects approximately 1 in 3 Americans," said Dr. Patrice Harris, an AMA board member.
Tuesday's vote is certain to step up pressure on health insurance companies to reimburse physicians for the time-consuming task of discussing obesity's health risks with patients whose body mass index exceeds 30. It should also encourage doctors to direct these patients to weight-loss programs and to monitor their often-fitful progress.
The federally funded Medicare program, which insures an estimated 13 million obese Americans who are over 65 or disabled, already covers the costs of "intensive behavioral therapy" for obese patients, as well as bariatric surgery for those with additional health conditions. But coverage for such obesity treatments has been uneven among private insurers.
Insurers who are members of the California Assn. of Health Plans cover many services to treat medical conditions associated with obesity, including bariatric surgery and diabetes, said President and Chief Executive Patrick Johnston.
The AMA's decision essentially makes diagnosis and treatment of obesity a physician's professional obligation. As such, it should encourage primary care physicians to get over their discomfort about raising weight concerns with obese patients. Studies have found that more than half of obese patients have never been told by a medical professional they need to lose weight — a result not only of some doctors' reluctance to offend but of their unwillingness to open a lengthy consultation for which they might not be reimbursed.
Past AMA documents have referred to obesity as an "urgent chronic condition," a "major health concern" and a "complex disorder." The vote now lifts obesity above the status of a health condition, disorder or marker for heightened risk of disease — as high cholesterol is for heart disease, for instance.
"As things stand now, primary care physicians tend to look at obesity as a behavior problem," said Dr. Rexford Ahima of University of Pennsylvania's Institute for Diabetes, Obesity and Metabolism. "This will force primary care physicians to address it, even if we don't have a cure for it."
The new designation follows a steep 30-year climb in Americans' weight — and growing public concern over the resulting tidal wave of expensive health problems. Treatment of such obesity-related illnesses as cardiovascular disease, Type 2 diabetes and certain cancers drives up the nation's medical bill by more than $150 billion a year, according to the Centers for Disease Control and Prevention.
Projected increases in the obesity rate could boost that figure by an additional $550 billion over the next 20 years, a recent Duke University study concluded.
In laying out the case for and against the redefinition of obesity, the AMA's Council on Science and Public Health argued that more widespread recognition of obesity as a disease "could result in greater investments by government and the private sector to develop and reimburse obesity treatments."
The Food and Drug Administration, which has approved just two new prescription weight-loss medications since 1999, would probably face increased pressure to approve new obesity drugs, spurring new drug development and more widespread prescribing by physicians, the council noted.
"The greater urgency a disease label confers" also might boost support for obesity-prevention programs such as physical education initiatives and reforms to school lunch, the council added. In addition, it speculated that "employers may be required to cover obesity treatments for their employees and may be less able to discriminate on the basis of body weight."
But the council also said that making obesity a disease could deepen the stigma attached to being overweight and doom some patients to endless nagging — even if they were otherwise healthy or had lost enough weight to improve their health.
It might also shift the nation's focus too much toward expensive drug and surgical treatments and away from measures to encourage healthy diets and regular exercise, the council wrote in a background memo for AMA members.
Dr. Daniel H. Bessesen, an endocrinologist and obesity expert at the University of Colorado Anschutz Medical Campus, called the AMA's shift "a double-edged sword." Though the semantic change may reflect "a growing awareness that obesity is not someone's fault," he worried that "the term disease is stigmatizing, and people who are obese don't need more stigmatizing."
AMA declares obesity a disease
http://www.latimes.com/news/science/la-sci-obesity-disease-20130619,0,4422080.story
Sent via Flipboard


